KDR and lung cancer: Blockage of the VEGF/VEGF receptor (VEGFR) signaling pathways, through mAbs, ligand inhibitors and TKIs, has shown to be clinically beneficial in several cancers including, but not limited to, CRC, breast cancer and lung cancer [125, 136–138].